Roopal Thakkar

8.4k citations

142 papers · 5.3k indexed · 4 hit papers · h-index 29

Impact in

Genetics top 0.5%
- Inflammatory Bowel Disease
Epidemiology top 0.5%
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders

Papers in

Genetics 111
- Inflammatory Bowel Disease 111
Gastroenterology 15
- Celiac Disease Research and Management 12

Co-authors: William J. Sandborn Andreas Lazar Geert D’Haens Walter Reinisch Jean‐Frédéric Colombel Anne Robinson Douglas C. Wolf Martina Kron
Journals: Gastroenterology (28 papers)Inflammatory Bowel Diseases (27 papers)The American Journal of Gastroenterology (21 papers)Journal of Crohn s and Colitis (19 papers)Gut (10 papers)
Partner nations: United States Germany France

In The Last Decade

Roopal Thakkar

124 papers receiving 5.1k citations

Hit Papers

align trajectories log scale

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis 2011 · 946 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 Gastroenterology
2011 Gut
2007 JAMA
2002 Hypertension

Peers

Countries citing papers authored by Roopal Thakkar

Since Specialization

Citations

This map shows the geographic impact of Roopal Thakkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roopal Thakkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roopal Thakkar more than expected).

Fields of papers citing papers by Roopal Thakkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roopal Thakkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roopal Thakkar. The network helps show where Roopal Thakkar may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Roopal Thakkar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roopal Thakkar Line = papers co-authored together Roopal Thakkar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis Journal of Gastroenterology ·Yasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, Toshifumi Hibi∥, Shirô Nakamura, Andreas Lazar, Anne Robinson, Martha Skup, Nael M. Mostafa, Bidan Huang, Roopal Thakkar, Mamoru Watanabe	2017	8
2	Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy Alimentary Pharmacology & Therapeutics ·J F Colombel, Bindia Jharap, William J. Sandborn, Brian G. Feagan, Laurent Peyrin‐Biroulet, Samantha Eichner, Anne Robinson, Nael M. Mostafa, Qian Zhou, Roopal Thakkar	2016	33
3	Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis Digestive Diseases and Sciences ·Stefano Guandalini, Namita Tundia, Roopal Thakkar, Dendy Macaulay, Harold Ehrensperger, Mahesh Fuldeore	2016	18
4	Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial Gastrointestinal Endoscopy ·Paul Rutgeerts, Walter Reinisch, Jean‐Frédéric Colombel, William J. Sandborn, Geert D’Haens, Joel Petersson, Qian Zhou, Annalisa Iezzi, Roopal Thakkar	2015	22
5	Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 The American Journal of Gastroenterology ·Jean–Frédéric Colombel, William J. Sandborn, Subrata Ghosh, Douglas C. Wolf, Remo Panaccione, Brian G. Feagan, Walter Reinisch, Anne Robinson, Andreas Lazar, Martina Kron, Bidan Huang, Martha Skup, Roopal Thakkar	2014	124
6	Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis Journal of Gastroenterology ·Yasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, Takayuki Matsumoto, Toshifumi Hibi∥, Anne Robinson, Nael M. Mostafa, Jingdong Chao, Vipin Arora, Anne Camez, Roopal Thakkar, Mamoru Watanabe	2013	133
7	Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease Gastroenterology ·Mark T. Osterman, William J. Sandborn, Jean–Frédéric Colombel, Anne Robinson, Winnie Lau, Bidan Huang, Paul F. Pollack, Roopal Thakkar, James D. Lewis	2013	129
8	52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants Inflammatory Bowel Diseases ·Walter Reinisch, William J. Sandborn, Remo Panaccione, Bidan Huang, Paul F. Pollack, Andreas Lazar, Roopal Thakkar	2013	85
9	Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure JACC Heart Failure ·Milton Packer, Wilson S. Colucci, Lloyd D. Fisher, Barry M. Massie, John R. Teerlink, James B. Young, Robert J. Padley, Roopal Thakkar, Leticia Delgado‐Herrera, Jeffrey E. Salon, Chris Garratt, Bidan Huang, Toni Sarapohja	2013	285
10	Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease Current Medical Research and Opinion ·William J. Sandborn, J F Colombel, Geert D’Haens, Scott E. Plevy, Julián Panés, Anne Robinson, P Pollack, Qian Zhou, Ilsup Shin, Roopal Thakkar	2013	21
11	PTU-110 Elevated C reactive protein in anti-TNF-naïve patients is associated with higher remission rates: Abstract PTU-110 Table 1 Gut ·William J. Sandborn, J F Colombel, Ilsup Shin, Qian Zhou, Roopal Thakkar	2012	2
12	PTU-108 Induction of remission with adalimumab in patients with moderate Crohn's disease: subanalysis of CLASSIC I: Abstract PTU-108 Table 1 Gut ·William J. Sandborn, J F Colombel, Ilsup Shin, Qian Zhou, Roopal Thakkar	2012	1
13	PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis: Abstract PWE-253 Table 1 Gut ·William J. Sandborn, Gert Van Assche, Roopal Thakkar, A. Lazar, Martina Kron, Mei Yang, Saagar Patel, J. Chao, Parvez Mulani	2012	2
14	Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn's disease: data from extend: Table 1 Gut ·W. Sandborn, J F Colombel, Kathleen G. Lomax, P Pollack, Roopal Thakkar, A. Camez, Lijuan Hua, Mei Yang, J. Chao, Parvez Mulani	2011	10
15	52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants: Table 1 Gut ·Walter Reinisch, William J. Sandborn, K. M. Veenstra, P Pollack, A. Lazar, Roopal Thakkar	2011	9
16	Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease Gut ·Edward V. Loftus, J. Chao, Mei Yang, P Pollack, G. Groppo, Roopal Thakkar, Parvez Mulani	2011	1
17	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut ·Walter Reinisch, William J. Sandborn, Daniël W. Hommes, G. D’Haens, Stephen B. Hanauer, Stefanie Schreiber, Remo Panaccione, Richard N. Fedorak, Mahar Nirmala, B Huang, Wendy Kampman, A. Lazar, Roopal Thakkar Hit paper breakdown →	2011	683
18	Levosimendan vs. Dobutamine: Outcomes for Acute Heart Failure Patients on β-Blockers in SURVIVE European Journal of Heart Failure ·Alexandre Mebazaa, Markku S. Nieminen, Gerasimos Filippatos, John G.F. Cleland, Jeffrey E. Salon, Roopal Thakkar, Robert J. Padley, Bidan Huang, Alain Cohen‐Solal	2009	117
19	Flushing ASsessment Tool (FAST©) Clinical Drug Investigation ·Ariane K. Kawata, Dennis A. Revicki, Roopal Thakkar, Ping Jiang, Scott Krause, Michael H. Davidson, Henry Punzi, Robert J. Padley	2009	18
20	Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study Journal of clinical lipidology ·William Insull, Jan Basile, Anthony Vo, Ping Jiang, Roopal Thakkar, Robert J. Padley	2009	23

About Roopal Thakkar

Roopal Thakkar is a scholar working on Genetics, Gastroenterology, Epidemiology, Speech and Hearing and Hepatology, having authored 142 papers that have together received 5.3k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (111 papers), Microscopic Colitis (88 papers), Health Systems, Economic Evaluations, Quality of Life (14 papers), Pharmaceutical studies and practices (13 papers), Autoimmune and Inflammatory Disorders (12 papers), Celiac Disease Research and Management (12 papers), Eosinophilic Esophagitis (11 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). The work is most often cited by research in Genetics (3.1k citations), Epidemiology (2.7k citations), Gastroenterology (341 citations), Cardiology and Cardiovascular Medicine (1.3k citations) and Endocrinology, Diabetes and Metabolism (571 citations). Roopal Thakkar has collaborated with scholars based in United States, Germany and France. Frequent co-authors include William J. Sandborn, Andreas Lazar, Geert D’Haens, Walter Reinisch, Jean‐Frédéric Colombel, Anne Robinson, Douglas C. Wolf, Martina Kron, Gert Van Assche and Mari Nishizaka. Their work appears in journals such as Gastroenterology, Inflammatory Bowel Diseases, The American Journal of Gastroenterology, Journal of Crohn s and Colitis and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact